Drug Profile
ASN 002 - Ascend Biopharmaceuticals
Alternative Names: Ad-IFNγ; Adenovirus interferon gamma; ASN-002 - Ascend; SP-002 - Stamford Pharmaceuticals; TG-1042Latest Information Update: 17 Apr 2024
Price :
$50
*
At a glance
- Originator Transgene
- Developer Ascend Biopharmaceuticals; Nantes University Hospital; Transgene
- Class Antineoplastics; Cancer vaccines; Immunotherapies; Synthetic vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Basal cell cancer
- No development reported Malignant melanoma
- Discontinued Cutaneous B-cell lymphoma; Cutaneous T-cell lymphoma
Most Recent Events
- 09 Apr 2024 Phase-II clinical trials in Basal cell cancer (Combination therapy, Late-stage disease) in USA (Intratumoural) (NCT06344052)
- 26 Sep 2022 Phase-II development is still ongoing for Basal cell cancer (Combination therapy, First-line therapy) in Australia (Intratumoural) (NCT04416516)
- 23 Jul 2020 Phase-II clinical trials in Basal cell cancer (Combination therapy, First-line therapy) in Australia (Intratumoural) (NCT04416516)